Individualizing Management of T2DM in the Hospital Setting to Reduce Macro and Microvascular Complications

Release Date :
October 26, 2018
Expiration Date :
October 26, 2019
FACULTY

Harold Bays, MD, FOMA, FTOS, FACC, FACE, FNLA
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center
Your Body Goal
Louisville, Kentucky

PROGRAM OVERVIEW

Over the past several years there has been an increasing call for patient-centered care in the treatment of T2DM. Although the control of blood glucose levels remains a clear objective in disease management, factors other than glycemic control parameters have been shown to exert significant influence on clinical outcomes and have therefore gained prominence in the decision-making process as well. Indeed, comorbidities and life expectancies are now considered to be central factors in determining how aggressive treatment should be. This, together with the growing range of therapeutic options and increased emphasis on multifactorial treatment strategies, has resulted in clinicians being faced with the daunting challenge of simultaneously taking into account a multitude of variables related to both physiological and behavioral characteristics specific to individual patients.

TARGET AUDIENCE

This educational initiative has been designed for hospital-based healthcare providers, including physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists involved in the management of patients with T2DM.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Summarize correlations between macro and microvascular complications of uncontrolled T2DM and hospitalization
  • Evaluate the risk/benefit profiles of novel T2DM therapies in achieving glycemic control and reducing vascular complications
  • Employ evidence-based strategies to individualize treatment for diverse patients with T2DM to achieve glycemic control and reduce hospitalizations from vascular complications
DIRECTIONS TO THE LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 26, 2018 through October 26, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integrity Continuing Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for a total of 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number –JA4008162-9999-18-404-H01-P)
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.1 contact hours. Designated for 0.6 hours of pharmacotherapy for Advance Practice Registered Nurses.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.
For information about ACPE or ANCC accreditation of this activity, please contact Postgraduate Institute for Medicine at (303) 799-1930 or inquires@pimed.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education and Postgraduate Institute for Medicine require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education and Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education and Postgraduate Institute for Medicine are committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Harold Bays, MD, FOMA, FTOS, FACC, FACE, FNLA

  • Consultant: Aegerion, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, ChromaDex, Esperion, Gemphire, Janssen, Johnson & Johnson, Kowa, Merck, Novartis, Prosciento, Regeneron, Sanofi
  • Research: Acasti, Alere, Allergan, Amarin, Amgen, Arena, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, ChromaDex, Dr. Reddy, Eisai, Esperion, Ferrer/Chiltern, Gan and Lee, Gemphire, Gilead, GlaxoSmithKline, Home Access, iSpecimen, Ionis, Janssen, Johnson & Johnson, MedImmune, Merck, Necktar, Nichi-Iko, Novartis, NovoNordisk, Omthera, Pfizer, Regeneron, Sanofi, Selecta, Takeda, TIMI
  • Speaker: Aegerion, Amarin, Amgen, Kowa, Regeneron, Sanofion, Sanofi

The following planner and manager, Michelle R. Rizzo, ELS, hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. The PIM planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine and Integrity Continuing Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.

This CEU/CNE activity is co-provided by Postgraduate Institute for Medicine and Integrity Continuing Education.

SUPPORTER ACKNOWLEDGMENT

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Continue to Pretest